The Seed Investor News Roundup - Cannabis Biotechs Could Be Big Pharma's Latest M&A Focus

Read our Medical Marijuana Compound Report for Free Today!

The next big innovation is unfolding now and it’s already creating a wave of multi-millionaire investors in the process

Read the Investors Guide To Newly Emerging Marijuana Markets

LEARN MORE

Cronos Group Announces Closing of Previously Announced $17 Million Bought Deal

A total of 5,476,190 common shares of Cronos Group were sold at a price of $3.15 per Share for aggregate gross proceeds of approximately $17.2 million

New Health Canada Licence Allows Maricann Group Inc. to Increase Cannabis Production by Over 480% to 6,250,000 grams

This new licence increases capacity to 6,250,000 grams on site at any one time. This is an increase from its previous annual licence that limited production to a total of 1,282,000 grams (930kg of dried marihuana and 352 kg of cannabis oil) per year. This new license represents an increase of over 480% of production capacity and is valid until October 9, 2020.

CannTrust™ Announces Receiving Health Canada Approval to Export Medical Marijuana Internationally and the Shipping of Medical Marijuana to Australia

Canntrust announces it has received Health Canada approval to export medical marijuana internationally to Countries where medical marijuana is legalized and that the Company has now begun shipping to Australia.

Canopy Growth and Delta 9 applaud Manitoba Cannabis plan

Canopy Growth Corporation (TSX: WEED) and Delta 9 Cannabis Inc. (TSX.V: NINE) applaud the framework today announced by the Province of Manitoba regarding adult-use cannabis production, distribution, and retail.

Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimerDisclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed investment advisor.

TheSeedInvestor.com
9375 E Shea Blvd Ste 100
Scottsdale 85260

info@theseedinvestor.com

To keep receiving emails from us, please add us to your address book.